Evidence map›Paper›PMID 33910619›Full record

ReviewArthritis research & therapy2021

Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.

Huai Leng Pisaniello, Mark C Fisher, Hamish Farquhar, Ana Beatriz Vargas-Santos, Catherine L Hill, Lisa K Stamp, Angelo L Gaffo

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arthritis research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06863701 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety Study for the Combination of Etoricoxib / Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2025 to 2027Enrolled72ConditionsGout Arthritis, Gout AttackArmsEtoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose
NCT07328022 phase3completednot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2025 to 2025Enrolled89ConditionsBursitis, Tendinitis, SynovitisArmsFixed Dose Etoricoxib + Betamethasone, Monotherapy Etoricoxib
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Controversies in Urate-Lowering Therapy for Gout: A Comprehensive Review.Gout, urate, and crystal deposition disease · 2025
    Article
  6. Article
  7. Article
  8. Gout therapy updated.Therapeutic advances in musculoskeletal disease · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Current state and prospects of gout treatment in Korea.The Korean journal of internal medicine · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Huai Leng PisanielloDiscipline of Medicine, Faculty of Health and Medical Sciences, the University of Adelaide, Adelaide, South Australia, Australia.
Mark C FisherHarvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
Hamish FarquharDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Ana Beatriz Vargas-SantosDepartment of Internal Medicine, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Catherine L HillDiscipline of Medicine, Faculty of Health and Medical Sciences, the University of Adelaide, Adelaide, South Australia, Australia.
Lisa K StampDepartment of Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0003-0138-2912
Angelo L GaffoDivision of Rheumatology and Clinical Immunology, University of Alabama, 1720 2nd Avenue South, Birmingham, AL, 35294, USA. agaffo@uabmc.edu.
University of Otago · NZHarvard University · USQueen Elizabeth Hospital · AUThe University of Adelaide · AUUniversidade do Estado do Rio de Janeiro · BRUniversity of Alabama at Birmingham Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3-5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m

Indexed as

GoutHyperuricemiaPharmaceutical PreparationsRenal Insufficiency, ChronicGout SuppressantsHumansSymptom Flare UpGout SuppressantsPharmaceutical PreparationsColchicineCorticosteroidsGoutGout flareInterleukin 1 inhibitorsNon-steroidal anti-inflammatoryTreatment

Identifiers

PMID33910619
PMCPMC8080370
OpenAlexW3158108545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.